JAGUAR HEALTH, INC. Warrants and Rights Outstanding, Measurement Input
JAGUAR HEALTH, INC. (JAGX) had Warrants and Rights Outstanding, Measurement Input of 5 Y as of 2025-03-31, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:WarrantsAndRightsOutstandingMeasurementInput · last filed 2026-08-19
- 2025-03-31: Warrants and Rights Outstanding, Measurement Input 5.00 Y.
| Period end | Warrants and Rights Outstanding, Measurement Input |
|---|---|
| 2025-03-31 | 5.00 Y 10-Q · filed 2026-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |